Article
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center.
JCO precision oncology - 1 Jun 2024
Nguyen D Grace, Morris Sarah A, Hamilton Alicia, Kwange Simeon O, Steuerwald Nury, Symanowski James, Moore Donald C, Hanson Sarah, Mroz Kaitlyn, Lopes Karine E, Larck Chris, Musselwhite Laura, Kadakia Kunal C, Koya Brinda, Chai Seungjean, Osei-Boateng Kwabena, Kalapurakal Sini, Swift Kristen, Hwang Jimmy, Patel Jai N
Abstract excerpt
PURPOSE: Fluoropyrimidine-related toxicity and mortality risk increases significantly in patients carrying certain DPYD genetic variants with standard dosing. We implemented DPYD genotyping at a multisite cancer center and evaluated its impact on dosing, toxicity, and hospitalization. METHODS: In this prospective observational study, patients receiving (reactive) or planning to receive (pretreatment)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.